174 related articles for article (PubMed ID: 38450950)
1. Adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes-A systematic review.
Holdt-Caspersen NS; Dethlefsen C; Vestergaard P; Hejlesen O; Hangaard S; Jensen MH
Pharmacol Res Perspect; 2024 Apr; 12(2):e1185. PubMed ID: 38450950
[TBL] [Abstract][Full Text] [Related]
2. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic medication adherence and glycaemic control among patients with type 2 diabetes mellitus: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.
Balkhi B; Alwhaibi M; Alqahtani N; Alhawassi T; Alshammari TM; Mahmoud M; Almetwazi M; Ata S; Kamal KM
BMJ Open; 2019 Jul; 9(7):e029280. PubMed ID: 31340969
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
[TBL] [Abstract][Full Text] [Related]
5. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
Luo Y; Bai R; Zhang W; Qin G
Front Endocrinol (Lausanne); 2024; 15():1333624. PubMed ID: 38362282
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
[TBL] [Abstract][Full Text] [Related]
7. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States.
Cai J; Wang Y; Baser O; Xie L; Chow W
J Med Econ; 2016 Dec; 19(12):1175-1186. PubMed ID: 27356271
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review.
Zhu J; Zhou Y; Li Q; Wang G
Adv Ther; 2023 Oct; 40(10):4216-4235. PubMed ID: 37515713
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.
Iglay K; Cartier SE; Rosen VM; Zarotsky V; Rajpathak SN; Radican L; Tunceli K
Curr Med Res Opin; 2015; 31(7):1283-96. PubMed ID: 26023805
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
12. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
[TBL] [Abstract][Full Text] [Related]
15. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
16. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs.
Saundankar V; Peng X; Fu H; Ascher-Svanum H; Rodriguez A; Ali A; Slabaugh L; Young P; Louder A
J Manag Care Spec Pharm; 2016 May; 22(5):467-82. PubMed ID: 27123910
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
[TBL] [Abstract][Full Text] [Related]
20. Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study.
Ofori-Asenso R; Liew D; Lalic S; Mazidi M; Magliano DJ; Ademi Z; Bell JS; Ilomaki J
Adv Ther; 2019 Nov; 36(11):3265-3278. PubMed ID: 31482509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
